Secrecy surrounds generic abortion pill manufacturer Evita Solutions

The mystery behind generic abortion pill maker Evita Solutions, LLC, is reminiscent of the original abortion pill maker approved in 2000 — Danco Laboratories, which has also been long shrouded in secrecy. Like Danco Laboratories, little is known about Evita Solutions, and thus far, no spokespersons of the company have been revealed.

Key Takeaways:

• Manufacturers of the generic abortion pill have been shrouded in secrecy.

• Last month, Trump's FDA approved a new generic version of the drug mifepristone from Eva Solutions, LLC.

• Little is known about Evita Solutions, except that the principal is Robert Patane and the company is located in Virginia.

• The only drug Evita Solutions manufactures is the generic abortion pill.

The Backstory:

Since the abortion pill mifepristone was first approved in the year 2000, changes have been made under the FDA's regulations of the drug.

The abortion pill timeline:

• Clinton FDA: approved the abortion  pill (mifepristone 200mg) in 2000.  The drug was approved in a regimen along with a second drug, misoprostol, for the “termination of pregnancy.”

• Obama FDA: removed important REMS safety regulations such as reporting adverse events other than deaths, expanded use of the drug from 7 to 10 weeks gestation, among other things in 2016.

• Trump FDA: approved the first generic abortion pill drug made by GenBioPro in April of 2019. 

• Biden FDA: weakened the REMS further by eliminating important in-person requirements and enabling the drug to be shipped by mail (2021) and dispensed in pharmacies (2023). 

• Trump FDA: approved the second generic abortion pill made by Evita Solutions, LLC in September of 2025. The drug application originally submitted by Evita Solutions LLC in 2021.

A REMS (Risk Evaluation and Mitigation Strategy) is a "drug safety program" the FDA can require of certain medications that carry "serious safety concerns." The most recently published REMS on the abortion pill is now dated September 2025.

In the FDA's approval letter, it told Evita, "Your REMS must be fully operational before you introduce your drug into interstate commerce." This is despite the fact that the Federal Comstock Act prohibits the mailing of abortion inducing drugs.

In past years, the Packard Foundation, an original investor of the abortion pill, and GenBioPro, the first approved generic version, granted nearly $24 million to Hopewell Fund, IPAS, and ReproHub to expand access to the drug.

What We Know:

Last month, President Trump's Food and Drug Administration (FDA) greenlit approval of Evita Solutions LLC, the second generic abortion pill approved by the Trump FDA.

"This approval brings the total number of American companies that produce mifepristone for abortion to 3, expanding supply at a time when access may be restricted in certain areas within the US. Mifepristone carries out about two-thirds of medical terminations of pregnancy," reported Pharmacy Times earlier this month. But few details are known.

According to Dun & Bradstreet, the principal for Evita Solutions — a pharmaceutical manufacturer — is Robert Patane, and the business is located in Glen Allen, Virginia, as Live Action News previously documented.

Very little information is available at the Virginia Secretary of State office, except that C T Corporation System is the registered agent, effective June 26, 2024.

Evita’s prescribing document shows the organization's contact address as 20055 Roanoke, VA. The document advises patients to read FDA labeling and contact Evita Solutions LLC at 866-718-0098 or medicalabortionplll.com for additional copies of the drug’s medication guide. 

Evita, like Danco Laboratories, appears to distribute only one drug — the abortion pill.

It seems Evita has an abortion-focused mission. The company stated online, "Evita Solutions believes that all people should have access to safe, affordable, high-quality, effective, and compassionate healthcare, including abortion care. We know that you can make the best choice for your body." Its website also states:

Medical abortion care is rife with medically unnecessary restrictions and social stigma in the United States. As a result, many people who choose to end a pregnancy may struggle to get the necessary care they need.

Evita Solutions believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live. We know that you can make the best choice for your body.

Evita claims to be committed to “accurate information,” telling potential customers that “a trusted network of prescribers are available, when and where they are needed.”

“Through our work, we assist the medical community in recognizing the utility and freedom that medical abortion provides patients, we seek to normalize abortion care, and we commit to making care accessible to all,” the website notes.

“Before prescribing mifepristone, inform the patient about the risk of these serious events. Ensure the patient knows whom to call and what to do, including going to an Emergency Room if none of the provided contacts are reachable, if they experience sustained fever, severe abdominal pain, prolonged heavy bleeding, or syncope, or if they experience abdominal pain or discomfort, or general malaise (including weakness, nausea, vomiting, or diarrhea) for more than 24 hours after taking misoprostol,” Evita’s abortion pill website warns.

However, like Danco Laboratories, Evita Solutions is shrouded in secrecy, and thus far, no spokespersons or principals of the company have been revealed, other than Patane.

Live Action News located a "Bob" Patane, who was President of Pharmacist Pharmaceutical, LLC (PPLLC) in 2013, when PPLLC previously joined with Novel Laboratories Inc and HPSRx Enterprises to offer the Levonorgestrel 1.5 mg Emergency Contraceptive (EC) tablet, the Plan B One-Step® generic equivalent.

Ironically, Vinta Gupta, formerly the CEO of Novel Laboratories, Inc, now Lupin Pharmaceuticals, happens to offer a Pregnot Kit consisting of Mifepristone and Misoprostol.

While it does not appear that Patane is connected to Lupin, it's unclear whether "Robert" and "Bob" are the same person.

However, PPLLC's filings led Live Action News to J&P Holding Company, which, according to register information at the Virginia Secretary of State's Office, the president of J&P Holding is a "Robert " Patane. Live Action News will continue to investigate the connections (if any) between Patane, J&P, and any others it uncovers.

What's Ahead:

"U.S. Senator Josh Hawley of Missouri has called on the Food and Drug Administration to explain its recent approval of a new generic version of the abortion drug Mifepristone. In a letter addressed to FDA Commissioner Marty Makary, Hawley described the agency’s decision as 'alarming,' saying it appeared to disregard scientific data while advancing what he characterized as an 'ideological agenda,'” reported KTTN.com.

The news outlet added, "The senator requested that Commissioner Makary respond by October 10, 2025, addressing several specific points related to the approval process. Hawley’s questions included:

• Whether Makary personally participated in the approval of the application ANDA 216616 and the nature of that involvement.

• A detailed timeline of the submission and approval process for ANDA 216616.

• An explanation of the FDA’s therapeutic equivalence evaluation for the generic, including whether the agency’s bioequivalence review considered risks of increased adverse events.

• Clarification on how the FDA factored recent safety data on mifepristone into its approval decision.

• Whether the agency considered the stated goals and mission of Evita Solutions LLC when approving the drug.

• Whether the new generic will remain on the market without adhering to potential future safety standards that may arise from the ongoing review and any updated Mifepristone Risk Evaluation and Mitigation Strategy (REMS).

Lawsuit Continues Challenge of Abortion Pill

An ongoing lawsuit is challenging the expansion of the abortion drug. 

The lawsuit, now named State of Missouri v. FDA, was originally filed in Amarillo, Texas, by doctors in the Alliance for Hippocratic Medicine (AHM), but in 2024, the U.S. Supreme Court ruled that those doctors did not have standing to sue.

In January 2025, U.S. District Judge Matthew Kacsmaryk ruled that the states of Missouri, Kansas, and Idaho could intervene and file a complaint in the lawsuit, but in May, Trump’s Department of Justice (DOJ) called for dismissal of the lawsuit.

In August, Texas and Florida petitioned the court to intervene — and now, one month later, the State of Louisiana, along with Rosalie Markezich, a Louisiana woman who claims she was the victim of the FDA's decision to allow abortion pills by mail, have filed a motion to do the same.

The venue for hearing the lawsuit was recently moved out of Texas where Judge Matthew Kacsmaryk was to hear the case and and will now be heard in Missouri. 

Consider This:

Live Action News has documented how approval of the drug in 2000 was secretive, including the hiding of the identities of experts who approved the drug. To date, the full record has yet to be unveiled, leaving many to question whether past or present FDA reviewers and experts may have had financial or other conflicts of interest that led to these approvals and expansions.

A February 2025 update, published by the FDA, tragically revealed that since 2000, “The estimated number of women who have used mifepristone in the U.S. for medical termination of pregnancy through the end of December 2024 is approximately 7.5 million women.”

Claiming that “adverse events cannot with certainty be causally attributed to mifepristone”  the FDA also reported that it “received reports of serious adverse events in patients who took mifepristone,” adding that according to the FDA's website, “[a]s of December 31, 2024, there were 36 reports of deaths in patients associated with mifepristone since the product was approved in September 2000…”